{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T11:56:15Z","timestamp":1771674975610,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":1462,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1097\/jto.0b013e31822e722f","type":"journal-article","created":{"date-parts":[[2011,10,4]],"date-time":"2011-10-04T21:06:56Z","timestamp":1317762416000},"page":"2083-2089","source":"Crossref","is-referenced-by-count":37,"title":["Skin Toxicities Compromise Prolonged Pemetrexed Treatment"],"prefix":"10.1016","volume":"6","author":[{"given":"Belen","family":"Eguia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Marie","family":"Ruppert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Fillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armelle","family":"Lavol\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Gounant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christelle","family":"Epaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Milleron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Moguelet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Wislez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille","family":"Frances","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Cadranel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/JTO.0b013e31822e722f_bib1","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1592\/phco.26.5.641","article-title":"Pemetrexed, a novel antifolate therapeutic alternative for cancer chemotherapy","volume":"26","author":"Villela","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1097\/JTO.0b013e31822e722f_bib2","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1634\/theoncologist.9-5-482","article-title":"FDA drug approval summaries: pemetrexed (alimta)","volume":"9","author":"Hazarika","year":"2004","journal-title":"Oncologist"},{"key":"10.1097\/JTO.0b013e31822e722f_bib3","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/1471-2407-8-216","article-title":"Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer","volume":"8","author":"Russo","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1097\/JTO.0b013e31822e722f_bib4","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S0140-6736(09)61497-5","article-title":"Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study","volume":"374","author":"Ciuleanu","year":"2009","journal-title":"Lancet"},{"key":"10.1097\/JTO.0b013e31822e722f_bib5","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy","volume":"22","author":"Hanna","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31822e722f_bib6","first-page":"545","article-title":"Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy","volume":"1","author":"Niyikiza","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"10.1097\/JTO.0b013e31822e722f_bib7","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1053\/sonc.2002.37465","article-title":"Pemetrexed safety and dosing strategy","volume":"29","author":"Niyikiza","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1097\/JTO.0b013e31822e722f_bib8","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/annonc\/mdf115","article-title":"Phase II trial of pemetrexed disodium (alimta, ly231514) in chemotherapy-na\u00efve patients with advanced non-small-cell lung cancer","volume":"13","author":"Clarke","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1097\/JTO.0b013e31822e722f_bib9","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.lungcan.2006.08.002","article-title":"Pemetrexed-induced edema of the eyelid","volume":"54","author":"Kurata","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e31822e722f_bib10","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.lungcan.2010.04.024","article-title":"Pemetrexed-induced edema of the eyelid","volume":"69","author":"Guhl","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e31822e722f_bib11","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1097\/JTO.0b013e3181d6b9e8","article-title":"Pemetrexed-induced fluid retention","volume":"5","author":"Bastos","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1097\/JTO.0b013e31822e722f_bib12","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0761-8425(07)91133-X","article-title":"Severe cutaneous toxicity after pemetrexed as second line treatment for a refractory non small cell lung cancer","volume":"24","author":"Tummino","year":"2007","journal-title":"Rev Mal Respir"},{"key":"10.1097\/JTO.0b013e31822e722f_bib13","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1159\/000232315","article-title":"Toxic epidermal necrolysis related to pemetrexed and carboplatin with vitamin B12 and folic acid supplementation for advanced non-small cell lung cancer","volume":"32","author":"Bosch-Barrera","year":"2009","journal-title":"Onkologie"},{"key":"10.1097\/JTO.0b013e31822e722f_bib14","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.lungcan.2005.06.006","article-title":"Radiation recall dermatitis with pemetrexed","volume":"50","author":"Hureaux","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e31822e722f_bib15","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.lungcan.2006.06.021","article-title":"Unsuccessful rechallenge with pemetrexed after a previous radiation recall dermatitis","volume":"54","author":"Barl\u00e9si","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e31822e722f_bib16","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.lungcan.2005.10.008","article-title":"Pemetrexed-associated urticarial vasculitis","volume":"51","author":"Lopes","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e31822e722f_bib17","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1183\/09031936.01.00275301","article-title":"The new World Health Organization classification of lung tumours","volume":"18","author":"Brambilla","year":"2001","journal-title":"Eur Respir J"},{"key":"10.1097\/JTO.0b013e31822e722f_bib18","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/JTO.0b013e31812d05d5","article-title":"The IASLC lung cancer staging project: validation of the proposals for revision of the t, n, and m descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours","volume":"2","author":"Groome","year":"2007","journal-title":"J Thorac Oncol"},{"key":"10.1097\/JTO.0b013e31822e722f_bib19","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1056\/NEJMp0911494","article-title":"The missing voice of patients in drug-safety reporting","volume":"362","author":"Basch","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0b013e31822e722f_bib20","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/00001813-199803000-00001","article-title":"Gemcitabine\u2014a safety review","volume":"9","author":"Aapro","year":"1998","journal-title":"Anticanc Drugs"},{"key":"10.1097\/JTO.0b013e31822e722f_bib21","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1001\/archderm.1995.01690140086015","article-title":"Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent","volume":"131","author":"Zimmerman","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.1097\/JTO.0b013e31822e722f_bib22","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/1097-0142(19950701)76:1<110::AID-CNCR2820760117>3.0.CO;2-9","article-title":"Docetaxel (taxotere) associated scleroderma-like changes of the lower extremities. A report of three cases","volume":"76","author":"Battafarano","year":"1995","journal-title":"Cancer"},{"key":"10.1097\/JTO.0b013e31822e722f_bib23","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1080\/000155501317208381","article-title":"Gemcitabine-induced acute lipodermatosclerosis-like reaction","volume":"81","author":"Chu","year":"2001","journal-title":"Acta Derm Venereol"},{"key":"10.1097\/JTO.0b013e31822e722f_bib24","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.jaad.2001.07.001","article-title":"Gemcitabine-associated scleroderma-like changes of the lower extremities","volume":"51","author":"Bessis","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1097\/JTO.0b013e31822e722f_bib25","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1078::AID-CNCR19>3.0.CO;2-T","article-title":"Cutaneous fibrosis induced by docetaxel: a case report","volume":"88","author":"Cleveland","year":"2000","journal-title":"Cancer"},{"key":"10.1097\/JTO.0b013e31822e722f_bib26","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.tips.2009.12.001","article-title":"Gender differences in drug toxicity","volume":"31","author":"Nicolson","year":"2010","journal-title":"Trends Pharmacol Sci"},{"key":"10.1097\/JTO.0b013e31822e722f_bib27","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/109158101317097728","article-title":"Gender-based differences in the toxicity of pharmaceuticals\u2013the food and drug administration's perspective","volume":"20","author":"Miller","year":"2001","journal-title":"Int J Toxicol"},{"key":"10.1097\/JTO.0b013e31822e722f_bib28","first-page":"370","article-title":"Cell cycle modulation by the multitargeted anti-folate, ly231514, increases the antiproliferative activity of gemcitabine","volume":"37","author":"Tonkinson","year":"1996","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1097\/JTO.0b013e31822e722f_bib29","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1056\/NEJMra0806188","article-title":"Scleroderma","volume":"360","author":"Gabrielli","year":"2009","journal-title":"N Engl J Med"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415317342?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415317342?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T02:17:18Z","timestamp":1560737838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086415317342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S1556086415317342"],"URL":"https:\/\/doi.org\/10.1097\/jto.0b013e31822e722f","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}